In the PD-1/PDL1 group (n = 362), the most used PD-1 inhibitors associated with hypophysitis were nivolumab, pembrolizumab, sintilimab, camrelizumab, tislelizumab, and toripalimab. Here, CD274 is linked to hypophysitis.